L. Hossenbaccus, S. Garvey, T. Walker, H. Botting, L. Steacy, A. Ellis
{"title":"专用微粒控制环境暴露单元(SPAC-EEU)对猫皮屑暴露的临床验证","authors":"L. Hossenbaccus, S. Garvey, T. Walker, H. Botting, L. Steacy, A. Ellis","doi":"10.1016/j.anai.2024.08.079","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, specifically <em>Felis domesticus</em> 1 (Fel d 1). We subsequently performed a clinical validation with cat-allergic and non-allergic participants.</div></div><div><h3>Methods</h3><div>Recruited participants attended a screening visit where eligibility was assessed. Successfully screened cat-allergic and non-allergic participants subsequently attended one of two 3-hour cat dander exposure sessions in the SPaC-EEU. Fel d 1 concentrations were determined using a Fel d 1-specific ELISA. Participants recorded symptom scores at 18 timepoints, between baseline and 24 hours post-onset of allergen exposure.</div></div><div><h3>Results</h3><div>Forty-five participants completed this study, 31 cat-allergics and 15 non-allergics. Twenty-five participants attended first session (median Fel d 1=36.1 ng/m<sup>3</sup>) and 21 participants attended second session (median Fel d 1=102.0 ng/m<sup>3</sup>). Total nasal symptom scores (TNSS) for allergic participants in both sessions were not significantly different (p<0.05) at any timepoint, hence results were combined. Allergic participants had significantly increased (p<0.01) TNSS at all timepoints, from 15 minutes to 24 hours post-exposure, compared to non-allergics. Peak nasal inspiratory flow as percent change from baseline was significantly decreased (p<0.05) for allergics compared to non-allergics from 1.0 to 2.5 hours. No clinically significant safety outcomes were reported in either session.</div></div><div><h3>Conclusion</h3><div>The SPaC-EEU can safely produce clinically relevant and meaningful nasal symptoms in only cat-allergic participants. We have proven that this facility is an effective and reliable clinical model for cat allergen-induced allergic rhinitis.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"133 6","pages":"Page S17"},"PeriodicalIF":5.8000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLINICAL VALIDATION OF THE SPECIALIZED PARTICULATE CONTROL ENVIRONMENTAL EXPOSURE UNIT (SPAC-EEU) FOR CAT DANDER EXPOSURE\",\"authors\":\"L. Hossenbaccus, S. Garvey, T. Walker, H. Botting, L. Steacy, A. Ellis\",\"doi\":\"10.1016/j.anai.2024.08.079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, specifically <em>Felis domesticus</em> 1 (Fel d 1). We subsequently performed a clinical validation with cat-allergic and non-allergic participants.</div></div><div><h3>Methods</h3><div>Recruited participants attended a screening visit where eligibility was assessed. Successfully screened cat-allergic and non-allergic participants subsequently attended one of two 3-hour cat dander exposure sessions in the SPaC-EEU. Fel d 1 concentrations were determined using a Fel d 1-specific ELISA. Participants recorded symptom scores at 18 timepoints, between baseline and 24 hours post-onset of allergen exposure.</div></div><div><h3>Results</h3><div>Forty-five participants completed this study, 31 cat-allergics and 15 non-allergics. Twenty-five participants attended first session (median Fel d 1=36.1 ng/m<sup>3</sup>) and 21 participants attended second session (median Fel d 1=102.0 ng/m<sup>3</sup>). Total nasal symptom scores (TNSS) for allergic participants in both sessions were not significantly different (p<0.05) at any timepoint, hence results were combined. Allergic participants had significantly increased (p<0.01) TNSS at all timepoints, from 15 minutes to 24 hours post-exposure, compared to non-allergics. Peak nasal inspiratory flow as percent change from baseline was significantly decreased (p<0.05) for allergics compared to non-allergics from 1.0 to 2.5 hours. No clinically significant safety outcomes were reported in either session.</div></div><div><h3>Conclusion</h3><div>The SPaC-EEU can safely produce clinically relevant and meaningful nasal symptoms in only cat-allergic participants. We have proven that this facility is an effective and reliable clinical model for cat allergen-induced allergic rhinitis.</div></div>\",\"PeriodicalId\":50773,\"journal\":{\"name\":\"Annals of Allergy Asthma & Immunology\",\"volume\":\"133 6\",\"pages\":\"Page S17\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Allergy Asthma & Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1081120624006240\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1081120624006240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
导言专用微粒控制环境暴露装置(SPaC-EEU)是一种受控过敏原挑战设施,最近成功通过了猫皮屑(特别是家猫皮屑 1(Fel d 1))暴露的技术验证。我们随后对对猫过敏和不过敏的参与者进行了临床验证。通过筛查的猫过敏者和非过敏者随后参加了在 SPaC-EEU 进行的两个 3 小时猫皮屑暴露疗程中的一个疗程。使用 Fel d 1 特异性酶联免疫吸附法测定 Fel d 1 的浓度。参与者在 18 个时间点(从基线到接触过敏原后 24 小时)记录症状评分。结果45 名参与者完成了这项研究,其中 31 名猫过敏者,15 名非过敏者。25 名参与者参加了第一次治疗(中位数 Fel d 1=36.1 纳克/立方米),21 名参与者参加了第二次治疗(中位数 Fel d 1=102.0 纳克/立方米)。在两个疗程中,过敏性参与者的鼻部症状总分(TNSS)在任何时间点都没有显著差异(p<0.05),因此结果合并计算。与非过敏者相比,过敏者在暴露后 15 分钟至 24 小时的所有时间点上的 TNSS 都明显增加(p<0.01)。从 1.0 小时到 2.5 小时,与非过敏者相比,过敏者的峰值鼻吸气流量(与基线相比的百分比变化)明显下降(p<0.05)。结论 SPaC-EEU 可以安全地在对猫过敏的参与者中产生临床相关和有意义的鼻部症状。我们已经证明,该设备是猫过敏原诱发过敏性鼻炎的有效、可靠的临床模型。
CLINICAL VALIDATION OF THE SPECIALIZED PARTICULATE CONTROL ENVIRONMENTAL EXPOSURE UNIT (SPAC-EEU) FOR CAT DANDER EXPOSURE
Introduction
The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, specifically Felis domesticus 1 (Fel d 1). We subsequently performed a clinical validation with cat-allergic and non-allergic participants.
Methods
Recruited participants attended a screening visit where eligibility was assessed. Successfully screened cat-allergic and non-allergic participants subsequently attended one of two 3-hour cat dander exposure sessions in the SPaC-EEU. Fel d 1 concentrations were determined using a Fel d 1-specific ELISA. Participants recorded symptom scores at 18 timepoints, between baseline and 24 hours post-onset of allergen exposure.
Results
Forty-five participants completed this study, 31 cat-allergics and 15 non-allergics. Twenty-five participants attended first session (median Fel d 1=36.1 ng/m3) and 21 participants attended second session (median Fel d 1=102.0 ng/m3). Total nasal symptom scores (TNSS) for allergic participants in both sessions were not significantly different (p<0.05) at any timepoint, hence results were combined. Allergic participants had significantly increased (p<0.01) TNSS at all timepoints, from 15 minutes to 24 hours post-exposure, compared to non-allergics. Peak nasal inspiratory flow as percent change from baseline was significantly decreased (p<0.05) for allergics compared to non-allergics from 1.0 to 2.5 hours. No clinically significant safety outcomes were reported in either session.
Conclusion
The SPaC-EEU can safely produce clinically relevant and meaningful nasal symptoms in only cat-allergic participants. We have proven that this facility is an effective and reliable clinical model for cat allergen-induced allergic rhinitis.
期刊介绍:
Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.